T cells expressing CD19-specific chimeric antigen receptors (CARs) mediate high complete response rates in patients with B cell malignancies. However, autologous cell products are costly and time-consuming to produce and demonstrate variability in potency and toxicity. Monomorphic CD1d-restricted Vα24-invariant natural killer T cells (NKTs) are not alloreactive like HLA-restricted T cells and therefore can be made from allogeneic donors without risking graft-versus-host disease. We generated a bank of healthy donor NKTs that co-express a CD19-CAR, IL-15, and shRNA targeting beta-2-microglobulin and CD74 to downregulate HLA class I and II expression, respectively. Five lots of CAR-NKTs have been produced for this bank with each lot averaging 14.8 ± 2.5 days in culture, yielding 1.18 - 2.27x1010 cells per lot and an average NKT purity of 98.99% ± 1.02%. We are assessing the safety, persistence, and efficacy of this allogeneic product in ANCHOR, a first-in-human phase 1 dose-escalation trial for patients with relapsed/refractory B cell non-Hodgkin's lymphoma (NHL) and relapsed acute B lymphoblastic leukemia (ALL)(NCT00840853). No dose-limiting or grade 2+ toxicities related to CAR-NKTs have been observed. Seven NHL patients have been infused with CAR-NKTs so far at three dose levels (DL1:1x107, DL2:3x107, and DL3:1x108 CAR-NKT cells/m2), and three achieved objective responses including two complete responses. Additionally, one of two ALL patients treated on DL1 achieved a complete response. Though we did not detect CAR-NKTs in the peripheral blood of patients on DL1, we did find evidence of CAR-NKT proliferation that peaked one week after infusion in two NHL patients on DLs 2 and 3. CAR-NKTs were also found in tumor tissue from NHL patient biopsies at weeks one and five post-infusion. Our data indicate that allogeneic CAR-NKTs are well tolerated and can produce objective responses in relapsed/refractory NHL/ALL patients, suggesting that NKTs represent a promising platform for “off-the-shelf” cancer immunotherapy.